Bedrijfsoverzicht
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical entity focused on developing advanced therapies designed to improve patient outcomes for populations suffering from cardiometabolic disease. The company operates within the healthcare sector, specifically targeting the biotechnology industry, which implies a high reliance on research and development to bring novel compounds to market. As of the latest data, the company holds a market capitalization of $4.00 billion and generates annual revenue of $22.50 million, employing approximately 100 staff members. These valuation metrics and revenue figures suggest that the market places significant value on the company's pipeline assets, particularly its oral low-dose cholesteryl ester transfer protein (CETP) inhibitor known as Obicetrapib, despite the relatively small current revenue base compared to its market capitalization.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $22.50 million, yet it recorded a net income of -$203,819,008 and an EBITDA of -$225,463,008, revealing a substantial gap between top-line sales and bottom-line profitability driven by heavy operational expenditures. This significant disparity indicates a cost structure heavily weighted towards research and development activities and clinical trial expenses typical of a biotechnology firm in the late-stage phase. The free cash flow stands at -$112,909,872, which reflects a high consumption of cash reserves required to sustain ongoing clinical trials and operational overhead before the company achieves commercial revenue milestones. Despite the negative cash flow, the company maintains a robust cash position of $636.24 million, providing substantial financial flexibility to fund future operations without immediate need for external financing. The gross margin is reported at 100.0%, indicating that the cost of goods sold is currently negligible or zero, likely due to the pre-commercialization stage of its products, while the operating margin is -206187.5% and profit margin is 0.0%, highlighting the intense investment phase where expenses far outpace revenue. In terms of leverage, total debt amounts to only $202,000, resulting in a debt-to-equity ratio of 0.03, which suggests a highly conservative balance sheet with minimal reliance on borrowed capital. The current ratio is 7.88, demonstrating an extremely strong ability to meet short-term obligations with its liquid assets. Furthermore, the return on equity is -28.3% and the return on assets is -17.3%, metrics that reflect the current inability to generate returns on invested capital due to significant accumulated losses rather than operational inefficiency.
Waarderingsbeoordeling
The valuation metrics present a unique picture for a loss-making biotechnology company, with a trailing twelve-month P/E ratio listed as N/A and a forward P/E of -25.43, implying that the market expects earnings to turn positive in the future to justify the current price. The price-to-book ratio stands at 5.82, indicating that the stock trades at a significant premium relative to its tangible book value, a common characteristic for companies with valuable intellectual property portfolios. Alternative valuation measures such as the price-to-sales ratio of 177.60 and an EV/EBITDA of -14.90 suggest that the market is pricing the company primarily on its pipeline potential and asset value rather than current financial performance. Regarding trading ranges, the 52-week high is $42.00 and the 52-week low is $14.92, meaning the current price sits within this range but the specific percentage distance from the high or low depends on the real-time share price not provided in the static data. The stock exhibits a beta of 0.13, which indicates that the share price is significantly less volatile than the broader market, moving with much lower sensitivity to general market fluctuations.
Growth & Income
Revenue growth year-over-year is reported at -99.8%, while earnings growth is N/A, illustrating that the company is in a contraction phase regarding reported revenue as it pivots resources entirely toward clinical development rather than commercial scaling. Since the earnings growth is N/A and the company is currently unprofitable with a net loss exceeding $200 million, the growth profile is defined by clinical trial progress rather than traditional revenue expansion, meaning earnings cannot grow faster than revenue in the traditional sense until commercialization occurs. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash is reinvested into research, development, and clinical trials rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by a complete reliance on capital appreciation and pipeline advancement, with no income generation from dividends or current operations to support investor returns.